Anti-CTLA-8/IL-17a Antibody (Ixekizumab)
Catalog No.
F1282
Anti-CTLA-8/IL-17a Antibody (Ixekizumab)
Featured Products
Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD < 3 pM). Ixekizumab directly blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members. Ixekizumab is being studied in moderate to severe plaque psoriasis.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
146.44 kDa
Dry ice
1143503-69-8
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
Taltz, LY2439821
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q16552
Human, Cynomolgus
Unconjugated
Monoclonal
Protein A
IgG4SP
ELISA, FACS, Kinetics, Functional assay, Animal Model
CTLA-8 / IL-17a
Please avoid freeze-thaw cycles.